Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) is a clinical-stage biotechnology company pioneering bispecific antibody therapeutics for cancer treatment through its Biclonics® platform. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments shaping the company's trajectory in immuno-oncology.
Find timely updates on Merus' investigational therapies, including progress across multiple cancer indications. Track key milestones such as regulatory feedback, partnership expansions with pharmaceutical collaborators, and financial performance updates. Our aggregation ensures efficient monitoring of material events without promotional bias.
Content spans clinical data disclosures, research collaborations with industry leaders like Incyte and Lilly, intellectual property developments, and financial reporting. Each update is categorized for quick scanning while maintaining technical accuracy required for biotech analysis.
Bookmark this page for streamlined access to Merus' evolving story in multispecific antibody development. Combine our news repository with SEC filings and scientific publications for comprehensive investment research approach.
Merus has announced promising interim data from an ongoing phase 1/2 trial of its bispecific antibody, petosemtamab, in combination with pembrolizumab for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). As of March 6, 2024, the trial showed a 67% overall response rate among 24 evaluable patients. Responses were observed across different PD-L1 expression levels and HPV status, with a favorable safety profile. Merus plans to initiate a phase 3 registration trial by the end of 2024. The data will be presented at the ASCO Annual Meeting on June 3, 2024, and a conference call for investors is scheduled for May 28, 2024.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced the publication of abstracts for MCLA-145 and MCLA-129 at the 2024 ASCO® Annual Meeting.
On June 2, 2024, from 11:30 a.m. to 1:00 p.m. CT, a rapid oral session will present interim data from a Phase I study of MCLA-145 in advanced/metastatic solid tumors. MCLA-145 showed a disease control rate of 68% and was well-tolerated at the recommended dose of 40 mg every three weeks.
On June 3, 2024, from 1:30 to 4:30 p.m. CT, a poster presentation will cover the efficacy and safety of MCLA-129 in non-small cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations. Full presentations will be available on the Merus website.
Merus has announced the publication of an abstract on petosemtamab combined with pembrolizumab for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). The interim clinical data from 26 patients, as of November 6, 2023, shows a 60% response rate among 10 evaluable patients. The combination was well-tolerated with no significant overlapping toxicities.
The abstract will be presented at the 2024 ASCO Annual Meeting in Chicago, from May 31 to June 4, 2024. Merus will discuss the full dataset during a conference call on May 28, 2024. The company remains optimistic about the safety and efficacy of petosemtamab, particularly noting the low rate of severe adverse events and infusion-related reactions.
Merus N.V. announced that the U.S. FDA granted Breakthrough Therapy Designation (BTD) for petosemtamab in the treatment of recurrent or metastatic head and neck squamous cell carcinoma. This follows a Fast Track Designation for the same indication in 2023. The BTD is based on ongoing phase 1/2 trial data, with plans to provide updated efficacy and safety data later in 2024. BTD aims to accelerate drug development for serious conditions where the drug shows potential for significant improvement over existing therapies. Merus intends to engage with the FDA for a potential Biologics License Application submission.
Merus N.V. announced financial results for Q1 2024 and provided updates on its innovative oncology treatments. Petosemtamab in combination with pembrolizumab showed promising results in HNSCC, Zeno BLA accepted for priority review by FDA for NRG1+ NSCLC and PDAC. Cash runway expected into 2027. Collaboration with Incyte, Eli Lilly, and Gilead progressing well. Financially, a decrease in collaboration revenue but an increase in R&D and G&A expenses reported.
Merus N.V. announced that the U.S. FDA has accepted a priority review for the Biologics License Application of the bispecific antibody zenocutuzumab (Zeno) for NRG1+ NSCLC and PDAC. If approved, Zeno will be the first targeted therapy for NRG1+ cancer, offering a potential breakthrough in treatment options for patients.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
